ArticleJournal of Cancer2012
Cell-free Circulating miRNA Biomarkers in Cancer.
Article in Journal of Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 1 synthesis or guideline pooled it, 155 citations in OpenAlex.
- Role of Cancer Associated Fibroblast (CAF) derived miRNAs on head and neck malignancies microenvironment: a systematic review.BMC cancer · 2025Pooled it
- Trial
- Identification and validation of reference genes for qPCR detection of serum microRNAs in colorectal adenocarcinoma patients.PloS one · 2013Trial
- Tumor cell plasticity in non-small cell lung cancer: the role of microRNA and implications for diagnosis, prognosis and treatment.Translational cancer research · 2026Review
- Review
- Endocrine-disrupting chemicals as prostate carcinogens.Nature reviews. Urology · 2025Review
- Potential diagnostic and prognostic biomarkers of pediatric Burkitt lymphoma identified through miRNA expression profiling.Pediatric research · 2025Article
- MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.Frontiers in molecular neuroscience · 2024Review
- MicroRNA in lung cancer-a novel potential way for early diagnosis and therapy.Journal of applied genetics · 2023Review
- Multiplexed smFRET Nucleic Acid Sensing Using DNA Nanotweezers.Biosensors · 2023Article
- An efficient model for predicting human diseases through miRNA based on multiple-types of contrastive learning.Frontiers in microbiology · 2023Article
- Investigating the tumor-immune microenvironment through extracellular vesicles from frozen patient biopsies and 3D cultures.Frontiers in immunology · 2023Article
- Review
- AllergoOncology: Role of immune cells and immune proteins.Clinical and translational allergy · 2022Review
- Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022Article
- Multiplexed Liquid Biopsy and Tumor Imaging Using Surface-Enhanced Raman Scattering.Biosensors · 2021Review
- Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential.International journal of molecular sciences · 2021Review
- MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2021Review
- Role of miR153 and miR455-5p Expression in Oral Squamous Cell Carcinoma Isolated from Plasma.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Analysis of the expression levels and clinical value of miR-365 and miR-25 in serum of patients with non-small cell lung cancer.Oncology letters · 2020Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Considerable attention and an enormous amount of resources have been dedicated to cancer biomarker discovery and validation. However, there are still a limited number of useful biomarkers available for clinical use. An ideal biomarker should be easily assayed with minimally invasive medical procedures but possess high sensitivity and specificity. Commonly used circulating biomarkers are proteins in serum, most of which require labor-intensive analysis hindered by low sensitivity in early tumor detection. Since the deregulation of microRNA (miRNA) is associated with cancer development and progression, profiling of circulating miRNAs has been used in a number of studies to identify novel minimally invasive miRNA biomarkers. In this review, we discuss the origin of the circulating cell-free miRNAs and their carriers in blood. We summarize the clinical use and function of potentially promising miRNA biomarkers in a variety of different cancers, along with their downstream target genes in tumor initiation and development. Additionally, we analyze some technical challenges in applying miRNA biomarkers to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.